Declerck P - Search Results

1

Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians.

Barbier L, Vandenplas Y, Simoens S, Declerck P, Vulto AG, Huys I. Barbier L, et al. Among authors: declerck p. J Pharm Policy Pract. 2021 Jun 22;14(1):53. doi: 10.1186/s40545-021-00330-x. J Pharm Policy Pract. 2021. PMID: 34158128 Free PMC article.

2

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies.

Moorkens E, Jonker-Exler C, Huys I, Declerck P, Simoens S, Vulto AG. Moorkens E, et al. Among authors: declerck p. Front Pharmacol. 2016 Jun 29;7:193. doi: 10.3389/fphar.2016.00193. eCollection 2016. Front Pharmacol. 2016. PMID: 27445826 Free PMC article. Review.

3

The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape.

Moorkens E, Meuwissen N, Huys I, Declerck P, Vulto AG, Simoens S. Moorkens E, et al. Among authors: declerck p. Front Pharmacol. 2017 Jun 8;8:314. doi: 10.3389/fphar.2017.00314. eCollection 2017. Front Pharmacol. 2017. PMID: 28642701 Free PMC article.

4

Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2-Biosimilar and Originator Etanercept in the Outpatient Setting.

Moorkens E, Simoens S, Troein P, Declerck P, Vulto AG, Huys I. Moorkens E, et al. Among authors: declerck p. BioDrugs. 2019 Jun;33(3):299-306. doi: 10.1007/s40259-019-00346-5. BioDrugs. 2019. PMID: 30945206 Free PMC article.

5

Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1-Biosimilar and Originator Infliximab in the Hospital Setting.

Moorkens E, Simoens S, Troein P, Declerck P, Vulto AG, Huys I. Moorkens E, et al. Among authors: declerck p. BioDrugs. 2019 Jun;33(3):285-297. doi: 10.1007/s40259-019-00345-6. BioDrugs. 2019. PMID: 30945207 Free PMC article.

6

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars.

Barbier L, Declerck P, Simoens S, Neven P, Vulto AG, Huys I. Barbier L, et al. Among authors: declerck p. Br J Cancer. 2019 Jul;121(3):199-210. doi: 10.1038/s41416-019-0480-z. Epub 2019 Jul 1. Br J Cancer. 2019. PMID: 31257362 Free PMC article. Review.

7

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review.

Barbier L, Ebbers HC, Declerck P, Simoens S, Vulto AG, Huys I. Barbier L, et al. Among authors: declerck p. Clin Pharmacol Ther. 2020 Oct;108(4):734-755. doi: 10.1002/cpt.1836. Epub 2020 Apr 30. Clin Pharmacol Ther. 2020. PMID: 32236956 Free PMC article.

8

Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging.

Barbier L, Mbuaki A, Simoens S, Declerck P, Vulto AG, Huys I. Barbier L, et al. Among authors: declerck p. Front Med (Lausanne). 2022 Mar 9;9:820755. doi: 10.3389/fmed.2022.820755. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35355594 Free PMC article.

9

Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking.

Barbier L, Simoens S, Declerck P, Vulto AG, Huys I. Barbier L, et al. Among authors: declerck p. Front Pharmacol. 2022 Jul 12;13:821616. doi: 10.3389/fphar.2022.821616. eCollection 2022. Front Pharmacol. 2022. PMID: 35903323 Free PMC article.

10

Biosimilars: controversies as illustrated by rhGH.

Declerck PJ, Darendeliler F, Góth M, Kolouskova S, Micle I, Noordam C, Peterkova V, Volevodz NN, Zapletalová J, Ranke MB. Declerck PJ, et al. Curr Med Res Opin. 2010 May;26(5):1219-29. doi: 10.1185/03007991003719642. Curr Med Res Opin. 2010. PMID: 20302553 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

310 results

Search Page

Filters